Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

Phase 2

Conditions: Rectal Cancer

Interventions: Other: Laboratory test
Other: Medical history and physical examination
Other: BW and height
Other: Performance status
Other: Creatinine clearance
Other: Biomarker
Radiation: Contrasting CT
Other: Adverse event
Other: HBs antigen and HCV antibody
Other: Endoscopy
Other: HBs antibody and HBc antibody
Drug: L-OHP (85 mg/m2)
Drug: S-1
Drug: L-OHP (130mg/m2)
Drug: l-LV
Drug: 5-FU

First Posted Date: 2014-10-31

Last Posted Date: 2014-10-31

Lead Sponsor: Clinical Research Support Center Kyush

Target Recruit Count: 110

Registration Number: NCT02280070

Locations: 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵
Kurume University Hospital, Kurume, Japan

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Albumin Bound Paclitaxel
Drug: S-1

First Posted Date: 2014-08-29

Last Posted Date: 2017-07-27

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 73

Registration Number: NCT02229058

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Phase 2

Terminated

Conditions: Rectum Cancer
Esophagus Cancer
Stomach Cancer
Small Bowel Cancer
Colon Cancer

Interventions: Drug: S-1
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2014-08-13

Last Posted Date: 2018-08-28

Lead Sponsor: Heikki Joensuu

Target Recruit Count: 20

Registration Number: NCT02216149

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib
Drug: S-1
Drug: Oxaliplatin

First Posted Date: 2014-05-02

Last Posted Date: 2021-02-15

Lead Sponsor: Zhejiang University

Registration Number: NCT02129322

Locations: 🇨🇳
First affiliated hospital, Zhejiang University, Hangzhou, China

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: nanoparticle albumin-bound paclitaxel
Drug: S-1

First Posted Date: 2014-04-28

Last Posted Date: 2016-12-22

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 60

Registration Number: NCT02124317

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine/cisplatin
Drug: Capecitabine
Drug: S-1/cisplatin
Drug: S-1
Drug: Capecitabine/oxaliplatin
Drug: 5-fluorouracil
Drug: 5-fluorouracil/oxaliplatin

First Posted Date: 2014-04-15

Last Posted Date: 2020-10-23

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 111

Registration Number: NCT02114359

Locations: 🇰🇷
Yeongnam University Medical Center, Daegu, Korea, Republic of
🇰🇷
Kyungpook National University Medical Center, Daegu, Korea, Republic of
🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

and more 11 locations

Study of S-1 Plus LV for Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: LV

First Posted Date: 2014-03-18

Last Posted Date: 2014-03-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 39

Registration Number: NCT02090153

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Gaungzhou, Guangdong, China

A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC

Phase 4

Conditions: Hepatocellular Carcinoma

Interventions: Drug: S-1

First Posted Date: 2013-11-28

Last Posted Date: 2013-11-28

Lead Sponsor: Zhu Xu

Target Recruit Count: 110

Registration Number: NCT01997957

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

First Line Chemotherapy for Advanced Cancer

Phase 2

Terminated

Conditions: Gastric Cancer

Interventions: Drug: albumin-bounded paclitaxel
Drug: S-1

First Posted Date: 2013-11-11

Last Posted Date: 2016-06-14

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT01980810

Locations: 🇨🇳
Department of Medical Oncology,Cancer Hostpital and Institute,CAMS, Beijing, China

Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer

Phase 4

Conditions: Breast Neoplasms
Neoadjuvant Therapy

Interventions: Drug: S-1
Drug: 5-FU

First Posted Date: 2013-05-08

Last Posted Date: 2013-05-08

Lead Sponsor: Shandong University

Target Recruit Count: 240

Registration Number: NCT01849380

Locations: 🇨🇳
the Second Hospital of Shandong Universtity, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy